Ocumension Therapeutics
歐康維視生物
(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1477)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 30, 2026 AND APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

The board of directors (the "**Board**") of Ocumension Therapeutics (the "**Company**") announces that:

(i) all the resolutions as set out in the notice of the annual general meeting (the "**Annual General Meeting**") dated June 9, 2026 (the "**Notice**") were duly passed by the shareholders of the Company (the "**Shareholders**") as ordinary resolutions by way of poll at the Annual General Meeting of the Company held at 56th Floor, One Museum Place Office Building, No. 669 Xinzha Road, Shanghai, PRC on Tuesday, June 30, 2026 at 10:00 a.m.;

(ii) Mr. Ting Yuk Anthony WU ("**Mr. Wu**") retired as an independent non-executive Director at the Annual General Meeting and therefore ceased to be the chairman of the audit committee of the Board (the "**Audit Committee**") and a member of each of the remuneration committee (the "**Remuneration Committee**") and nomination committee ("**Nomination Committee**") of the Board; and

(iii) Ms. Beibei ZHUANG ("**Ms. Zhuang**") was elected as an independent non-executive Director at the Annual General Meeting and was appointed to succeed Mr. Wu in his positions on the Board committees.

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON JUNE 30, 2026

The Board is pleased to announce the poll results of the Annual General Meeting. References are made to the Company's circular in connection with the Annual General Meeting dated June 9, 2026 (the "**Circular**") and the Notice. Unless the context requires otherwise, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

The voting results in respect of the resolutions proposed at the Annual General Meeting were as follows:

ORDINARY RESOLUTIONS				Number of Votes (%)	
				For	**Against**
1.	To receive and adopt the audited consolidated financial statements of the Company and its subsidiaries and the reports of the Directors and auditor for the year ended December 31, 2025.			240,601,709 (100.000000%)	0 (0.000000%)
2.	(A)	To ratify, confirm, and approve all acts, decisions, and documents executed by Mr. Zhenyu ZHANG in his capacity as a Director of the Company during the period from the conclusion of the Company's annual general meeting held in 2025 up to the date of the Annual General Meeting;		240,601,709 (100.000000%)	0 (0.000000%)
	(B)	To re-elect the following retiring Directors:			
		(i)	Dr. Lian Yong CHEN as a non-executive Director;	237,516,955 (98.717900%)	3,084,754 (1.282100%)
		(ii)	Mr. Yanling CAO as a non-executive Director; and	240,434,272 (99.930409%)	167,437 (0.069591%)
		(iii)	Mr. Zhenyu ZHANG as an independent non-executive Director;	240,446,818 (99.935623%)	154,891 (0.064377%)
	(C)	To elect Ms. Beibei ZHUANG as an independent non-executive Director; and		240,601,709 (100.000000%)	0 (0.000000%)
	(D)	To authorize the Board to fix the remuneration of the Directors.		240,530,709 (99.970491%)	71,000 (0.029509%)
3.	To re-appoint Deloitte Touche Tohmatsu as the auditor of the Company and authorize the Board to fix its remuneration.			238,345,599 (99.062305%)	2,256,110 (0.937695%)
4.	(A)	To give a general mandate to the Directors to allot, issue and deal with additional shares (including any sale or transfer of treasury shares out of treasury) not exceeding 20% of the issued shares of the Company (excluding treasury shares) as of the date of this resolution.		236,126,349 (98.139930%)	4,475,360 (1.860070%)
	(B)	To give a general mandate to the Directors to repurchase shares not exceeding 10% of the issued shares of the Company (excluding treasury shares) as of the date of this resolution.		240,601,709 (100.000000%)	0 (0.000000%)
	(C)	To extend the authority given to the Directors pursuant to ordinary resolution no. 4(A) to issue shares by adding to the issued shares of the Company (excluding treasury shares) the number of shares repurchased under ordinary resolution no. 4(B).		233,615,349 (97.096297%)	6,986,360 (2.903703%)

ORDINARY RESOLUTIONS		Number of Votes (%)	
		For	**Against**
5.	To approve the refreshment of the Scheme Mandate Limit under the 2021 Share Option Scheme and the 2021 Share Award Scheme of 8% of the issued Shares of the Company (excluding treasury Shares) as of the date of this resolution.	236,731,070 (98.391267%)	3,870,639 (1.608733%)
6.	To approve the refreshment of the Service Provider Sublimit of 0.8% of the issued Shares of the Company (excluding treasury Shares) as of the date of this resolution.	234,220,070 (97.347634%)	6,381,639 (2.652366%)
As more than 50% of the votes were cast in favor of each of the above resolutions, all the resolutions were passed as ordinary resolutions at the Annual General Meeting.			

Please refer to the Notice for the full text of the resolutions proposed at the Annual General Meeting.

The total number of issued Shares (excluding treasury Shares) as of the date of the Annual General Meeting was 815,382,414 Shares, which was the total number of Shares entitling the Shareholders to attend and vote for or against all the resolutions. As of the date of the Annual General Meeting, there were (i) 20,949,500 treasury Shares held by the Company (including any treasury Shares held or deposited with CCASS), and accordingly no voting rights attaching to such treasury Shares were exercised at the Annual General Meeting; and (ii) no Shares repurchased by the Company which were pending cancellation and should be excluded from the total number of Shares for the purpose of the Annual General Meeting. Pursuant to Rule 17.05A of the Listing Rules, the Trustee, holding 3,845,931 unvested Shares under the share schemes of the Company, abstained from voting on the resolutions proposed at the Annual General Meeting.

To the best knowledge, information and belief of the Board after having made all reasonable enquiries, (i) there were no Shares entitling the holders to attend and abstain from voting in favor at the Annual General Meeting as set out in Rule 13.40 of the Listing Rules; (ii) there were no restrictions on any Shareholder casting votes on any of the proposed resolutions at the Annual General Meeting; and (iii) save as disclosed above, no other Shareholder was required under the Listing Rules to abstain from voting on the resolutions proposed at the Annual General Meeting. No Shareholder has stated his/her/its intention in the Circular to vote against or to abstain from voting on the resolutions proposed at the Annual General Meeting.

Save for Mr. Zhenyu ZHANG who was unable to attend the Annual General Meeting due to other engagements, all other Directors attended the Annual General Meeting, either in person or by means of telecommunication.

Computershare Hong Kong Investor Services Limited, the Hong Kong branch share registrar and transfer office of the Company, acted as the scrutineer for counting of votes at the Annual General Meeting.

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF BOARD COMMITTEES

Reference is made to the announcement of the Company dated March 26, 2026 in relation to the proposed appointment of an independent non-executive Director and change in composition of Board committees. With effect from the conclusion of the Annual General Meeting, Mr. Wu has retired as an independent non-executive Director and ceased to be the chairman of the Audit Committee and a member of each of the Remuneration Committee and the Nomination Committee. The Board would like to express its sincere gratitude to Mr. Wu for his invaluable contribution to the Company during his tenure of office.

Following the passing of the relevant resolution at the Annual General Meeting, Ms. Zhuang has been appointed as an independent non-executive Director, the chairwoman of the Audit Committee and a member of each of the Remuneration Committee and the Nomination Committee, with effect from the conclusion of the Annual General Meeting. The biographical details of Ms. Zhuang are set out below:

Ms. Zhuang, aged 45, has over 15 years of experience in auditing and financial services. From August 2006 to May 2025, she worked at PricewaterhouseCoopers Zhong Tian LLP (普華永道中天會計師事務所(特殊普通合夥)) where her last position was an audit partner. In June 2025, she joined BDO China Shu Lun Pan Certified Public Accountants LLP (立信會計師事務所(特殊普通合夥)) as an audit partner. Ms. Zhuang possesses in-depth professional knowledge and extensive practical experience in the field of auditing, with a thorough and comprehensive understanding of Chinese Accounting Standards for Business Enterprises, International Financial Reporting Standards, and relevant regulatory requirements. She has led audit engagements for numerous companies and is well-positioned to contribute to the Group's financial reporting, internal controls and compliance matters.

Ms. Zhuang graduated from Nanjing Audit University (南京審計大學) in June 2003 with a bachelor's degree in financial management. She also obtained the Certified Internal Auditor (CIA) qualification in November 2005, the China Certified Public Accountant (CPA) qualification certificate in June 2008, and the CPA practicing certificate in May 2010.

Ms. Zhuang has entered into a letter of appointment with the Company with an initial term of three years commencing from June 30, 2026, which is subject to retirement by rotation and re-election as and when required under the articles of association of the Company, or vacation from office pursuant to any applicable laws from time to time, until terminated in accordance with the terms and conditions of the appointment letter or by either party giving to the other not less than three months' prior notice in writing. Pursuant to her letter of appointment, Ms. Zhuang will be entitled to a director's fee of HK$200,000 per annum, which was recommended by the Remuneration Committee and determined by the Board with reference to her academic and professional qualifications and experience, her duties and level of responsibilities within the Group for the relevant position, as well as the Company's remuneration policy and prevailing market conditions. Ms. Zhuang may also receive additional benefits as the Board or its authorized person(s) may, in their absolute discretion, deem appropriate for her term of appointment as an independent non-executive Director.

As of the date of this announcement, Ms. Zhuang does not have, and is not deemed to have, any interests or short positions in any Shares, underlying Shares or debentures of the Company and its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong). Save as disclosed above, Ms. Zhuang has not held any directorships in other listed public companies in Hong Kong or overseas during the three years immediately preceding her appointment and does not have any other major appointments or professional qualifications. Ms. Zhuang is not related to any Director, senior management, substantial Shareholder or controlling Shareholder of the Company and does not hold any other position with the Company or other members of the Group. Ms. Zhuang has not been subject to any penalty or punishment imposed by any relevant authorities or stock exchanges.

Ms. Zhuang has confirmed that (i) she has satisfied all the factors for independence as set out in Rule 3.13(1) to (8) of the Listing Rules; (ii) she has no past or present financial or other interest in the business of the Group or connection with any core connected person (as defined in the Listing Rules) of the Company; and (iii) there are no other factors that may affect her independence at the time of her appointment. Ms. Zhuang has obtained the legal advice referred to under Rule 3.09D of the Listing Rules prior to her appointment, and confirmed that she understood her obligations as a Director under the Listing Rules.

Save as disclosed above, the Board is not aware of any other matters that need to be brought to the attention of the Shareholders in connection with the appointment of Ms. Zhuang as an independent non-executive Director, or any other information that needs to be disclosed pursuant to Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

The Board would like to welcome Ms. Zhuang to the Board.

By order of the Board
Ocumension Therapeutics
Dr. Lian Yong CHEN
Chairman and Non-executive Director

Hong Kong, June 30, 2026

As of the date of this announcement, the Board comprises Mr. Ye LIU and Dr. Zhaopeng HU as executive Directors, Dr. Lian Yong CHEN, Mr. Yanling CAO and Dr. Qin XIE as non-executive Directors, and Ms. Beibei ZHUANG, Mr. Yiran HUANG and Mr. Zhenyu ZHANG as independent non-executive Directors.